CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer

Annals of Surgical Oncology

Volumn 8, Issue 5, 2001, Pages 389-401

  Habal, N ^a   Gupta, R K ^a   Bilchik, A J ^a   Yee, R ^a   Leopoldo, Z ^a   Ye, W ^a   Elashoff, R M ^a   Morton, D L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Active specific immunotherapy; CancerVax; Colon cancer; Immune response; TA90 antigen

Indexed keywords

BCG VACCINE; TUBERCULIN; TUMOR CELL VACCINE;

ACTIVE IMMUNIZATION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG MECHANISM; DRUG SYNTHESIS; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; INJECTION; MALE; METASTASIS; PREDICTION; TREATMENT OUTCOME; VACCINATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BCG VACCINE; CANCER VACCINES; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 0035013150     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2001.8.5.389     Document Type: Article

References (48)

1. Current status of human melanoma vaccines: Can they control malignant melanoma?
2. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
3. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma
4. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients
5. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens
6. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival
7. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in-vitro cellular immune response
8. Isolation and characterization of 90-100 kDa tumor-associated antigen in the sera of melanoma patients
9. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
10. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma
11. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
12. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients
13. TA90-IC, a new marker for colon cancer
14. Active specific immunotherapy in malignant melanoma
15. Reporting results of cancer treatment
16. Hepatic colorectal metastasis: Current status of surgical therapy
17. Treatment of colorectal liver metastases
18. Therapy for advanced colorectal cancer
19. New drugs in the treatment of colorectal carcinoma
20. Cryotherapy for liver tumors
21. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: Results of a pilot clinical trial
22. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature
23. Levamisole and interleukin-2 for advanced malignancy
24. Artifactual CEA elevation due to human anti-mouse antibodies
25. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients
26. Phase II study of dual-isotope 13 II-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer
27. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients
28. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
29. Polynucleotide-mediated immunization of cancer
30. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
31. Biological therapy: Approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target
32. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
33. Pharmacological administration of granulocyte/macrophage colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
34. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
35. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
36. Active specific immunotherapy for stage II and stage III human colon cancer: A randomized trial
37. Active specific immunotherapy for stage II and stage III human colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283
38. An enhanced humoral immune response predicts improved disease-free and overall survival in AJCC stage II melanoma patients receiving polyvalent melanoma vaccine (CancerVax)
39. Serum immunoglobulins in colorectal cancer
40. Immunoglobulins intrinsic to colorectal carcinoma: An unfavorable prognostic association with IgM
41. Serum immunoglobulins in colorectal cancer
42. Cell adhesion molecules and colon cancer
43. The biology of the immune system
44. Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor associated antigen
45. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients
46. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen
47. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccine
48. Colorectal cancer